The COVID-19 vaccine GBP510, which is being developed by Korean companies, is undergoing phase 3 global clinical trials. The recruitment of 4,000 people from six countries has been completed.

Today (18th), the government held the 26th meeting of the pan-government TF to support clinical trials of COVID-19 vaccines and treatments to discuss the progress of the development of COVID-19 vaccines in Korea. The meeting was attended by Ryu Geun-hyuk, the second vice minister of the MOHW, related ministries, and private experts, and SK Bioscience President Ahn Jae-yong announced the progress of clinical trials for the COVID-19 vaccine currently under development.

In Korea, eight companies are cur